Medicxi is a European life sciences venture capital firm focused on biotech and healthcare investing. Founded in 2016 by the former Index Ventures life sciences team, it pioneered an 'asset-centric' approach, building new companies around one or a few experimental products rather than broad platforms.
44% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (3 deals in the last 12 months vs 6 prior). Average disclosed round size is $85.2M (across 27 rounds with reported amounts).
Portfolio
33
Fund Size
$581M
Top Stage
Series B
Last 12 Mo
4
Team
Nick Williams
Partner
Shyam Masrani
Partner
Ben Perry
Investment Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
39 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Fore Biotherapeutics | Unknown | $67.4M | Jul 2026 |
| EEthyreal | Unknown | $101M | Jun 2026 |
| AAltesa Biosciences | Series B | $75M | Feb 2026 |
 D3 Bio | Series C | — | Dec 2025 |
| Fore Biotherapeutics | Series D | $38M | May 2025 |
| FFore Bio | Series D | $38M | May 2025 |
 Curevo | Series B | $110M | Mar 2025 |
| CCurevo Vaccine | Series B | $110M | Jan 2025 |
| CCurevo Vaccine (Curevo) | Series B | $110M | Jan 2025 |
 RAPT Therapeutics | Series D | $150M | Dec 2024 |
| OOttimo | Series A | $140M | Dec 2024 |
 Vicebio | Series B | $100M | Sep 2024 |
 ProfoundBio | Series B | $112M | Feb 2024 |
| OOttimo | Series A | $140M | Jan 2024 |
 Rivus Pharmaceuticals | Series B | $132M | Sep 2022 |
| MMiroBio | Series B | $97M | Jan 2022 |
| RRivus Pharma | Series B | $132M | Jan 2022 |
| Rivus Pharmaceuticals | Series A | $35M | Jul 2021 |
| VVersanis Bio | Series A | $70M | Jan 2021 |
 SynOx Therapeutics Ltd | Series A | — | Nov 2020 |
| PPalladio Biosciences | Series B | — | Sep 2020 |
| AAlderaan Biotechnology | Series A | — | Jan 2020 |
| YYukin Therapeutics | Unknown | — | Jun 2019 |
 Morphogen-IX | Series B | $18.4M | Dec 2018 |
| MMorphogen-IX - Centessa Therapeutics | Series B | $18.4M | Dec 2018 |
Page 1 of 2
Top Co-Investors
OrbiMed12 shared
RA Capital Management9 shared
Longitude Capital5 shared
HBM Healthcare Investments5 shared
Sanofi Ventures4 shared
SR One4 shared
Samsara BioCapital4 shared
Osage University Partners3 shared
Wellington Management3 shared
Cormorant Asset Management3 shared
Decheng Capital3 shared
Atlas Venture3 shared
Forbion2 shared
Bain Capital Life Sciences2 shared
venBio2 shared
TCG2 shared
Perceptive Advisors2 shared
3B Future Health Fund2 shared
LG Technology Ventures2 shared
SymBiosis2 shared
Last updated: 8 September 2026